PMID- 30402125
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2018
DP  - 2018
TI  - Protective Effects of Chinese Traditional Medicine Longhu Rendan against 
      Atherosclerosis via Negative Regulation of LOX-1.
PG  - 4812639
LID - 10.1155/2018/4812639 [doi]
LID - 4812639
AB  - Longhu Rendan (LHRD), a Chinese traditional compound medicine, has a remarkable 
      treatment effect on motion sickness for about half a century. However, the role 
      of LHRD in atherosclerosis treatment is still unclear. In this study, LHRD 
      treatment significantly diminished total cholesterol (TC), triglyceride (TG), and 
      low-density lipoprotein cholesterol (LDL-C) levels in apolipoprotein E 
      gene-knockout (ApoE(-/-)) mice fed with high fat and high cholesterol diet 
      (western diet). Besides, LHRD treatment significantly reduced atherosclerotic 
      lesion and plaques formation in both aortic roots and aortic trees. Furthermore, 
      immunofluorescence staining in aortic roots demonstrated that LHRD treatment 
      inhibited lectin-like oxidized low-density-lipoprotein receptor-1 (LOX-1) 
      expression in atherosclerotic plaques. These results indicated that LHRD 
      ameliorated atherosclerosis via reducing serum levels of TC, TG, and LDL-C as 
      well as LOX-1 expression, subsequently attenuating atherosclerotic lesion and 
      lipid deposition. In conclusion, LHRD could significantly attenuate experimental 
      atherosclerosis and might be a novel potential drug for the prevention and 
      treatment of atherosclerosis.
FAU - Yan, Sishan
AU  - Yan S
AD  - Guangdong Pharmaceutical University, Guangzhou, Guangdong 510006, China.
FAU - Wu, Teng
AU  - Wu T
AD  - Key Laboratory of Cardiovascular Disease and Department of Pathophysiology, 
      Nanjing Medical University, Nanjing, Jiangsu 211166, China.
FAU - Li, Ning
AU  - Li N
AD  - Guangdong Pharmaceutical University, Guangzhou, Guangdong 510006, China.
FAU - Zhang, Lingyi
AU  - Zhang L
AD  - Guangdong Pharmaceutical University, Guangzhou, Guangdong 510006, China.
FAU - Song, Jun
AU  - Song J
AD  - Guangdong Pharmaceutical University, Guangzhou, Guangdong 510006, China.
FAU - Xu, Yunzheng
AU  - Xu Y
AD  - Guangdong Pharmaceutical University, Guangzhou, Guangdong 510006, China.
FAU - Wang, Shumei
AU  - Wang S
AD  - Guangdong Pharmaceutical University, Guangzhou, Guangdong 510006, China.
AD  - Key Laboratory of Digital Quality Evaluation of Chinese Materia Medica of State 
      Administration of TCM, Guangzhou 510006, China.
AD  - Engineering & Technology Research Center for Chinese Materia Medica Quality of 
      Guangdong Province, Guangzhou 510006, China.
FAU - Ding, Liqin
AU  - Ding L
AD  - Shanghai Zhonghua Pharmaceutical Co., Ltd., Shanghai 201707, China.
FAU - Jin, Jiahua
AU  - Jin J
AD  - Shanghai Zhonghua Pharmaceutical Co., Ltd., Shanghai 201707, China.
FAU - Liu, Ying
AU  - Liu Y
AUID- ORCID: 0000-0003-1917-7263
AD  - Guangdong Pharmaceutical University, Guangzhou, Guangdong 510006, China.
FAU - Lan, Tian
AU  - Lan T
AUID- ORCID: 0000-0002-5783-6883
AD  - Guangdong Pharmaceutical University, Guangzhou, Guangdong 510006, China.
LA  - eng
PT  - Journal Article
DEP - 20181008
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC6196979
EDAT- 2018/11/08 06:00
MHDA- 2018/11/08 06:01
PMCR- 2018/10/08
CRDT- 2018/11/08 06:00
PHST- 2018/05/12 00:00 [received]
PHST- 2018/08/23 00:00 [accepted]
PHST- 2018/11/08 06:00 [entrez]
PHST- 2018/11/08 06:00 [pubmed]
PHST- 2018/11/08 06:01 [medline]
PHST- 2018/10/08 00:00 [pmc-release]
AID - 10.1155/2018/4812639 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2018 Oct 8;2018:4812639. doi: 
      10.1155/2018/4812639. eCollection 2018.